康希诺：24价肺炎球菌多糖结合疫苗临床试验获批

Core Viewpoint - The company announced that its 24-valent pneumococcal polysaccharide conjugate vaccine has received approval from the National Medical Products Administration for clinical trials aimed at preventing infections caused by 24 serotypes of pneumococcus [1] Group 1 - The vaccine, referred to as PCV24, covers the main circulating serotypes of pneumococcus [1] - It utilizes a covalent binding method between polysaccharide antigens and protein carriers, employing a dual carrier technology [1] - The vaccine is intended for administration to individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by the specified pneumococcal serotypes [1]